Breast cancer conventional serum biomarkers are carcinoembryonic antigen (CEA) and cancer antigen 15-3 (CA15-3), however their clinical use raised several concerns regarding their low sensitivity and specificity. The gene discussed is CEACAM5; the disease is breast carcinoma.